Earnings Roundup

Cubist Pharmaceuticals Inc., of Lexington, Mass., reported net sales of Cubicin (daptomycin) of $153.7 million for the first quarter, up 14 percent over the same period last year. The firm posted total revenues of $162.5 million, which beat consensus estimates of $156 million. Net income totaled $22.6 million, or 38 cents per share.